INVO Bioscience will exhibit at the 2022 Annual Meeting of the Pacific Coast Reproductive Society (PCRS)


SARASOTA, Florida., March 24, 2022 /PRNewswire/ — INVO Bioscience, Inc. (NASDAQ: INVO), INVOcell developers®an advanced fertility treatment technology currently available, showcases the INVOcell solution at the 2022 Pacific Coast Reproductive Society (PCRS) Annual Meeting, taking place March 23-27 at the Renaissance Esmeralda Resort & Spa in Indian Wells, California.

INVO Bioscience, Inc. is a medical device company focused on commercializing the world’s only in vivo intravaginal culture (IVC) system, INVOcell®, an effective and affordable treatment for patients with infertility. (PRNewsfoto/INVO Bioscience, Inc.)

Chris MyerINVO Senior Vice President, Business Development, Americas, and Bojan (Bo) MitrovicPhD, Director of Sales for INVO, USA, will both be available at Booth #314 to discuss INVOcell with the broader Assisted Reproductive Technology (ART) physician community.

Steve ShumCEO of INVO Bioscience, said, “A key part of our commercialization strategy is to synchronize and take a broader, more comprehensive and direct approach to our efforts in the United States. clinics who have already trained on the INVOcell device and the IVC treatment process, as well as to introduce our solution to other clinic operators wishing to expand their treatment options and overall capacity by introducing patients to INVOcell. »

The Pacific Coast Reproductive Society is a multidisciplinary medical society that provides continuing medical education (CME) for physicians and allied health professionals. The PCRS Annual Meeting provides an exceptional forum for the exchange of information and the advancement of reproductive medicine ideologies in a relaxed, collegial setting. Session topics have been carefully selected to bring you the highest quality, innovative CME designed and presented by thought leaders in reproductive medicine.

About INVO Bioscience

We are a commercial-stage fertility company expanding access to advanced treatments worldwide. Our core mission is to implement new medical technologies aimed at increasing the availability of affordable, high-quality, patient-centered fertility care. Our patented medical device, the INVOcell®allow a revolution live vaginal incubation method. This treatment solution is the world’s first intravaginal culture technique for incubation of oocytes and sperm during fertilization and early embryo development. This technique, referred to as “IVC”, provides patients with a more natural and intimate experience compared to other assisted reproductive technology (ART) treatments. The IVC procedure can provide comparable results at a fraction of the cost of the traditional method in vitro fertilization (IVF) and is a significantly more effective treatment than intrauterine insemination (IUI). Our go-to-market strategy involves opening dedicated INVO centers focused on the INVOcell offering® and IVC procedure (with 3 centers in North America now operational), as well as the sale of our technological solution in existing fertility clinics. For more information, please visit

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company is relying on the protections of the Private Securities Litigation Reform Act of 1995. All statements regarding our expected future financial condition, results of operations, cash flows, financing plans, business strategies, products and services, competitive positions, growth opportunities, management plans and objectives for future operations, and statements that include words such as “anticipate”, “if”, “believe”, “plan”, “estimate” , “expect”, “intend”, “may”, “could”, “should”, “should” and other similar expressions are forward-looking statements. All forward-looking statements involve risks , uncertainties and contingencies, many of which are beyond our control, which may cause actual results, performance or achievements to differ materially from anti cipated. Factors that could cause actual results to differ materially from those contained in the forward-looking statements include those set forth in our filings at We are under no obligation (and expressly disclaim any such obligation) to update or change our forward-looking statements, whether as a result of new information, future events or otherwise.



View original content to download multimedia: -301509640.html

SOURCE INVO Bioscience, Inc.


Comments are closed.